Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 8, 1997, Pages 585-589

  Huang, Y I Tsau ^a   Cheng, Yuh Ren ^a   Lin, Han Chieh ^a   Chen, Chieh Fu ^b   Hong, Chuang Ye ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Calcium channel antagonist; Portal hypertension; Radioactive microsphere method; Tetrandrine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; TETRANDRINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART INDEX; HEART RATE; HEMODYNAMICS; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN BLOOD FLOW; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030792514     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00490.x     Document Type: Article

References (31)

1. + channels. Life Sci. 1995; 56: 295-306.
2. Liu Q-Y, Li B, Gang J-M, Karpinski E, Pang PKT. Tetrandrine, a antagonist: effects and mechanisms of action in vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 1995; 273: 32-9.
3. Qian JQ, Thoolen MJMC, van Meel JCA, Timmermans PBMWM, van Zwieten PA. Hypotensive activity of tetrandrine in rats: investigation into its mode of action. Pharmacology 1983; 26: 187-97.
4. Xu Y, Rao M-R. Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Eur. J. Pharmacol. 1995; 278: 1-7.
5. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
6. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol. Ther. 1994; 61: 65-107.
7. Imperiale TF, Teran JC, McCullouch AJ. A meta-analysis of somatostatin vs. vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995; 109: 1289-94.
8. Reichen J, Le M. Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of liver. J. Clin. Invest. 1986; 78: 448-55.
9. Reichen J, Hirlinger A, Ha HR, Sagesser S. Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis. J. Hepatol. 1986; 3: 49-58.
10. Liu T-B, Lin H-C, Huang Y-T, Sun C-M, Hong C-Y. Portal hypotensive effects of tetrandrine and verapamil on portal hypertensive rats. J. Pharm. Pharmacol. 1997; 49: 85-8.
11. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am. J. Physiol. 1981 240: G371-5.
12. Huang Y-T, Wang G-F, Yang MCM, Chang S-P, Lin H-C, Hong C-Y. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J. Pharmacol. Exp. Ther. 1996; 278: 535-41.
13. Lin H-C, Yang MC-M, Hou M-C et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996; 23: 537-43.
14. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990; 11: 1066-78.
15. Kwan C-Y, Wang Z-L. Tetrandrine: a vasodilator of medicinal herb origin with a novel contractile effect on dog saphenous vein. Eur. J. Pharmacol. 1993; 238: 431-4.
16. 2- and norepinephrine-induced contractions of isolated rabbit main pulmonary arteries. Acta Pharmacol. Sin. 1986; 7: 37-40.
17. Zeng F-D, Shaw DH Jr, Ogilvie RI. Kinetic disposition and hemodynamic effects of tetrandrine in anesthetized dogs. J. Cardiovasc. Pharmacol. 1985; 7: 1034-39.
18. Lin H-C, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J. Hepatol. 1991; 13: 213-9.
19. Lin H-C, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal veinstenosed rats. Hepatology 1991; 14: 325-30.
20. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105: 1464-70.
21. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am. J. Physiol. 1987; 257: G52-7.
22. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18: 688-95.
23. Freeman JG, Barton JR, Record CO. Effect of isosorbide dinitrate, verapamil, and labetolol on portal pressure in cirrhosis. BMJ 1985; 291: 561-2.
24. Kong C-W, Lay C-S, Tsai Y-T et al. The hemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis. Hepatology 1986; 6: 423-6.
25. Lay C-S, Tsai Y-T, Kong C-W et al. Effects of verapamil on estimated hepatic blood flow in patients with HBsAg-positive cirrhosis. Hepatogastroenterology 1988; 35: 121-4.
26. Navasa M, Bosch J, Reichen J et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 1988; 8: 850-4.
27. Vinel JP, Caucanas JP, Combis JM, Cales P, Voigt JJ, Pascal JP. Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis. J. Hepatol. 1989; 8: 302-7.
28. Straumann A, Kiowski KGW, Bruendler H, Stalder GA. Hemodynamic effects of nifedipine on hepatic venous pressure gradient in patients with portal hypertension. Hepatogastroenterology 1986; 33: 101-4.
29. Koshy A, Hadengue A, Lee SS, Jiron MI, Lebrec D. Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis. Clin. Pharmacol. Ther. 1987; 42: 295-8.
30. Lay C-S, Tsai Y-T, Kong C-W et al. Lack of effects of nifedipine on hepatic hemodynamics in patients with HBsAg-positive cirrhosis. Liver 1987; 7: 223-7.
31. Iwao T, Toyonaga A, Ikegami M et al. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis. Am. J. Gastroenterol. 1992; 87: 326-31.